E Fund Management Co. Ltd. Acquires 5,231 Shares of DexCom, Inc. (NASDAQ:DXCM)

Key Points

• E Fund Management Co. Ltd. increased its stake in DexCom, Inc. by 53.2%, acquiring an additional 5,231 shares, bringing its total holdings to 15,056 shares valued at approximately $1,028,000.
• DexCom recently reported a quarterly earnings per share (EPS) of $0.48, exceeding analyst estimates of $0.45, with revenue of $1.16 billion.
• Analysts have a consensus rating of "Moderate Buy" for DexCom, with a price target averaging $99.89, reflecting positive market expectations.

E Fund Management Co. Ltd. boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 53.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,056 shares of the medical device company's stock after purchasing an additional 5,231 shares during the period. E Fund Management Co. Ltd.'s holdings in DexCom were worth $1,028,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Brighton Jones LLC lifted its stake in shares of DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock valued at $1,290,000 after acquiring an additional 11,946 shares during the last quarter. Bank Pictet & Cie Europe AG lifted its stake in shares of DexCom by 1.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company's stock valued at $8,637,000 after acquiring an additional 2,010 shares during the last quarter. Townsquare Capital LLC lifted its stake in shares of DexCom by 288.7% in the 4th quarter. Townsquare Capital LLC now owns 37,191 shares of the medical device company's stock valued at $2,892,000 after acquiring an additional 27,623 shares during the last quarter. Sagespring Wealth Partners LLC bought a new position in shares of DexCom in the 4th quarter valued at $418,000. Finally, Mariner LLC lifted its stake in shares of DexCom by 1.5% in the 4th quarter. Mariner LLC now owns 29,729 shares of the medical device company's stock valued at $2,312,000 after acquiring an additional 442 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Performance

Shares of DexCom stock opened at $79.96 on Thursday. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The business has a 50-day moving average price of $83.28 and a two-hundred day moving average price of $80.19. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $93.25. The company has a market cap of $31.36 billion, a P/E ratio of 55.53, a PEG ratio of 1.68 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period last year, the business posted $0.43 EPS. The business's revenue was up 15.2% compared to the same quarter last year. As a group, analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

DXCM has been the subject of a number of research reports. William Blair upgraded DexCom to a "strong-buy" rating in a research note on Thursday, July 31st. Oppenheimer increased their price target on DexCom from $95.00 to $102.00 and gave the company an "outperform" rating in a research note on Thursday, July 31st. The Goldman Sachs Group assumed coverage on DexCom in a research note on Friday, May 30th. They issued a "buy" rating and a $104.00 price target for the company. Raymond James Financial increased their price objective on DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a report on Thursday, July 31st. Finally, Truist Financial assumed coverage on DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 target price for the company. Four equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $99.89.

Insider Transactions at DexCom

In other news, Director Mark G. Foletta sold 2,750 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $83.13, for a total value of $228,607.50. Following the completion of the sale, the director directly owned 56,621 shares in the company, valued at $4,706,903.73. This trade represents a 4.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Michael Jon Brown sold 500 shares of the firm's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $41,400.00. Following the completion of the sale, the executive vice president owned 95,102 shares of the company's stock, valued at approximately $7,874,445.60. This represents a 0.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,656 shares of company stock valued at $2,412,191. 0.32% of the stock is currently owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.